title: A disintegrin and metalloproteinase (ADAM)-10 as a predictive factor for tocilizumab effectiveness in rheumatoid arthritis.
abstract: OBJECTIVE
  A disintegrin and metalloproteinase (ADAM)-10 is expressed in rheumatoid arthritis (RA). In this study, we focused on ADAM-10 as a predictive factor for the treatment with biologics in RA.
  
  
  METHODS
  The levels of ADAM-10 and fractalkine/CX3CL1 in RA and healthy controls serum were measured using enzyme-linked immunosorbent assays. Fifteen patients were treated with adalimumab (ADA), and 20 patients were treated with tocilizumab (TCZ).
  
  
  RESULTS
  ADAM-10 positively correlated with fractalkine/CX3CL1 in the sera of RA patients and was presented at a significantly higher level compared to that in normal serum (487 ± 80 pg/ml and 85 ± 33 pg/ml, respectively, p < 0.05). ADAM-10 highly correlates with fractalkine/CX3CL1 in the sera of RA patients. The level of ADAM-10 decreased after the treatment with TCZ but not with ADA. In addition, we found that the level of ADAM-10 in TCZ responders was significantly higher than that of the TCZ nonresponders at 24 weeks (619 ± 134 pg/ml and 109 ± 25 pg/ml, respectively). Multiple regression analysis showed that ADAM-10 was only identified as independent predictive variable for the improvement of DAS28 (ESR) at 24 weeks.
  
  
  CONCLUSIONS
  ADAM-10 may be a predictor of the effectiveness of TCZ in treating RA.
authors.affiliation: a Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan and.
authors.forename: Takeo
authors.initials: T
authors.lastname: Isozaki
authors.affiliation: a Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan and.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Nishimi
authors.affiliation: a Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan and.
authors.forename: Airi
authors.initials: A
authors.lastname: Nishimi
authors.affiliation: a Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan and.
authors.forename: Mayu
authors.initials: M
authors.lastname: Saito
authors.affiliation: a Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan and.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Miwa
authors.affiliation: b Department of Orthopedics , Showa University School of Medicine , Tokyo , Japan.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Toyoshima
authors.affiliation: b Department of Orthopedics , Showa University School of Medicine , Tokyo , Japan.
authors.forename: Katsunori
authors.initials: K
authors.lastname: Inagaki
authors.affiliation: a Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan and.
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kasama
mesh_terms: D000072197:ADAM10 Protein / Q000097:blood*; D000068879:Adalimumab / Q000008:administration & dosage / Q000009:adverse effects; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy; D054428:Chemokine CX3CL1 / Q000097:blood*; D000075743:Chemokine CXCL16 / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D054428:Chemokine CX3CL1; D000075743:Chemokine CXCL16; D000072197:ADAM10 Protein; D000068879:Adalimumab; C502936:tocilizumab
keywords: ADAM-10; Adalimumab; Predictive factor; Rheumatoid arthritis; Tocilizumab